FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immune Disease topics
Immune Disease
Autoimmune
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Immune Disorder
Transplant
Autoimmune Disorders
Type 1 Diabetes
Autoimmune Disorder
Proliferative Disorder
Signs And Symptoms
Proliferative
Antagonist
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Disease patents



      
           
This page is updated frequently with new Immune Disease-related patent applications. Subscribe to the Immune Disease RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Disease RSS RSS


Materials and methods for modulating immune responses

Materials and methods for modulating immune responses

Date/App# patent app List of recent Immune Disease-related patents
10/23/14
20140315917
 Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities patent thumbnailImidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..
10/23/14
20140315740
 Antigen array and diagnostic uses thereof patent thumbnailAntigen array and diagnostic uses thereof
A method of diagnosing an immune disease, or a predisposition thereto, in a subject is disclosed. The method comprises determining a capacity of immunoglobulins of the subject to specifically bind each antigen probe of an antigen probe set, wherein the antigen probe set comprises a plurality of antigen probes selected from the group consisting of at least a portion of a cell/tissue structure molecule, at least a portion of a heat shock protein, at least a portion of an immune system molecule, at least a portion of a homopolymeric polypeptide, at least a portion of a hormone, at least a portion of a metabolic enzyme, at least a portion of a microbial antigen, at least a portion of a molluscan antigen, at least a portion of a nucleic acid, at least a portion of a plant antigen, at least a portion of plasma molecule, and at least a portion of a tissue antigen, wherein the capacity is indicative of the immune disease or the predisposition thereto, thereby diagnosing the immune disease, or the predisposition thereto, in the subject..
10/23/14
20140314866
 Materials and methods for modulating immune responses patent thumbnailMaterials and methods for modulating immune responses
The present invention provides nanoparticle-coupled tolerogenic treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (sle), multiple sclerosis (ms), inflammatory bowel disease (ibd), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with graft versus host disease (gvhd) following hematopoietic stem cell transplantation..
10/23/14
20140314764
 Bi-specific antibodies for medical use patent thumbnailBi-specific antibodies for medical use
A bispecific antibody format devoid of an active fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on b-cells, for use in the treatment or prevention of b cell mediated autoimmune diseases.. .
10/23/14
20140314710
 Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment patent thumbnailIl-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
A novel approach to discover new drugs against ms and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (il-12), the p40 monomer (p40), the p40 homodimer (p402), and the il-23.
10/16/14
20140309158
 Compositions and methods for immunomodulation patent thumbnailCompositions and methods for immunomodulation
The invention relates to methods and reagents for the treatment of immunological diseases. In particular, the invention relates to isoforms of the c4b-binding protein (c4bp) lacking beta chains as well as to fragments and peptides derived thereof and to the uses of these polypeptides for the treatment of immunological diseases such as immunoinflammatory disease, sepsis, an autoimmune disease, transplant rejection, graft-versus-host disease and a hypersensitivity disease.
10/16/14
20140308281
 Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates patent thumbnailAntibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates
The invention concerns antibodies directed against cd127, i.e. The alpha chain of the receptor for interleukin7 (il-7), especially the receptor for human il-7 expressed on human cells (designated human il-7r alpha or il-7ra) or the tslp receptor.
10/16/14
20140308270
 Method and formulation for reducing aggregation of a macromolecule under physiological conditions patent thumbnailMethod and formulation for reducing aggregation of a macromolecule under physiological conditions
The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of 5% to 20% polyvinylpyrrolidone (pvp) with a molecular weight range of 2000 to 54,000 daltons. The invention further provides a method to minimize inflammation at the injection site during subcutaneous administration of a macromolecule.
10/16/14
20140308244
 Combination therapy for treatment of inflammatory demyelinating disease patent thumbnailCombination therapy for treatment of inflammatory demyelinating disease
Provided herein include combination therapies for the treatment of neurological inflammatory diseases, such as, for example, demyelinating autoimmune diseases, such as multiple sclerosis and neuromyelitis optica, etc. In various aspects and embodiments, the methods may include administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more second compounds, in one aspect, provided is a method of treating a demyelinating autoimmune disease (such as multiple sclerosis) that includes administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more compounds selected from the group consisting of a cytokine, a vitamin b, dimethyl fumarate (dmf, also referred to as bg-12) and fingolimod (gilenya)..
10/16/14
20140308238
 Immunomodulating compositions and methods of use thereof patent thumbnailImmunomodulating compositions and methods of use thereof
The invention is directed to β1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The β1-6 glucans of certain embodiments of the invention are enriched for o-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
10/16/14
20140308209
Soluble mediator
The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
10/09/14
20140303218
Nitrogen mustard derivatives
The disclosure includes compounds of formula (1): wherein x1, x2, q, z, r1, and r2 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds..
10/09/14
20140303140
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Wherein r1a, r1b, r2, r4, r5, r6a, r6b, r7, r8, w, x, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..
10/09/14
20140302070
Novel pd1 isoforms, and uses thereof for potentiating immune responses
In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
10/09/14
20140302058
Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..
10/09/14
20140301996
Methods for the treatment and prevention of inflammatory diseases
The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from helicobacter pylori activates nkt cells in a cd1d-restricted fashion, and is protective against ahr in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by nkt cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative nkt cells and foxp3+ treg cells.
10/09/14
20140301969
Metap-2 inhibitor polymersomes for therapeutic administration
The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising metap-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety..
10/02/14
20140296482
Method to screen for selective peptides that inhibit the biological activity of calcineurin
The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides lxvpc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (cn)-nfat and the phosphate activity of cn.
10/02/14
20140296480
Peptide secreted by lactobacillus plantarum with immunomodulating function
To summarize, the st peptide is considered to promote the process of immunologic ignorance of our gastrointestinal immune system toward the commensal bacteria of our gastrointestinal tract, thus favoring the mechanisms of oral tolerance. Therefore the st peptide could be used in immunotherapy, especially in the context of certain autoimmune diseases and certain inflammatory diseases..
10/02/14
20140296304
Pharmaceutically active disubstituted pyridine derivatives
The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase..
10/02/14
20140296252
1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..
10/02/14
20140296153
Oligodendrocyte differentiation
The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the loss of the myelin sheath that insulates the nerves) is an associated or causative feature. The data provided demonstrate the utility of the compounds and compositions according to this invention to promote oligodendrogenesis and myelination or remyelination..
10/02/14
20140296104
Genes differentially expressed by cumulus cells and assays using same to identify pregnancy competent oocytes
A genetic means of identifying “pregnancy competent” oocytes is provided. The means comprises detecting the level of expression of one or more genes that are expressed at characteristic levels (upregulated or downregulated) in cumulus cells derived from pregnancy competent oocytes.


Popular terms: [SEARCH]

Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2266

4083

70 - 0 - 78